ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Daiichi Sankyo and Amgen side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Daiichi SankyoAmgen
studies on the registry4991,088
open to participants now3750
phase 3 studies under way2150
reach primary completion within a year1135
programswith a study of their own in two years2024

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseDaiichi SankyoAmgen
Phase 1

Daiichi Sankyo: 7 of its 20 programs at phase 1

  1. DS1025Aphase 1
  2. DS3610Aphase 1
  3. DS5361Bphase 1
  4. DS9051Bphase 1
  5. valemetostatphase 1

and 2 more — sign in to see them all

35%

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%
Phase 225%

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%
Phase 3

Daiichi Sankyo: 4 of its 20 programs at phase 3

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. raludotatug deruxtecanphase 3
20%

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%
Approved, new studies

Daiichi Sankyo: 4 of its 20 programs at approved, new studies

  1. quizartinibapproved, new study
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study
20%

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Daiichi Sankyo3 readouts · 1 phase 3·

Daiichi Sankyo, Dec ’26: 1 program whose next study reaches primary completion

  1. raludotatug deruxtecanphase 3 · Dec 30 · NCT04707248
····

Daiichi Sankyo, May ’27: 1 program whose next study reaches primary completion

  1. quizartinibapproved, new study · May 1 · NCT03793478
····

Daiichi Sankyo, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. trastuzumab deruxtecanphase 3 · Oct 1 · NCT05950945
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Daiichi Sankyo

New programs 1

  • olomorasibphase 2 · first study · Oct 16 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 5

Where they overlap

Conditions where at least two of them have programs: 13 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionDaiichi SankyoAmgen
Carcinoma, Non-Small-Cell Lungboth · compare here

Amgen in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. sotorasibphase 3
  2. Pan-KRAS Inhibitor AMG 410phase 1
  3. tambotatug pelitecanphase 1
  4. romiplostimapproved, new study

Their studies: Amgen’s studies of Carcinoma, Non-Small-Cell Lung in search

Hypercholesterolemiaboth · compare here

Daiichi Sankyo in Hypercholesterolemia: 4 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Hypercholesterolemia in search

Amgen in Hypercholesterolemia: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Hypercholesterolemia in search

Hyperlipidemiasboth · compare here

Daiichi Sankyo in Hyperlipidemias: 4 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Hyperlipidemias in search

Amgen in Hyperlipidemias: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Hyperlipidemias in search

Dyslipidemiasboth · compare here

Daiichi Sankyo in Dyslipidemias: 3 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study
  3. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Dyslipidemias in search

Amgen in Dyslipidemias: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Dyslipidemias in search

Neoplasm Metastasisboth · compare here

Amgen in Neoplasm Metastasis: 1 program

  1. WRN Inhibitor AMG 436phase 1

Their studies: Amgen’s studies of Neoplasm Metastasis in search

Atherosclerosisboth · compare here

Daiichi Sankyo in Atherosclerosis: 1 program

  1. Ezetimibeapproved, new study

Their studies: Daiichi Sankyo’s studies of Atherosclerosis in search

Amgen in Atherosclerosis: 2 programs

  1. maridebart cafraglutidephase 3
  2. olpasiranphase 3

Their studies: Amgen’s studies of Atherosclerosis in search

Colorectal Neoplasmsboth · compare here

Daiichi Sankyo in Colorectal Neoplasms: 1 program

  1. olomorasibphase 2

Their studies: Daiichi Sankyo’s studies of Colorectal Neoplasms in search

Amgen in Colorectal Neoplasms: 2 programs

  1. sotorasibphase 3
  2. afliberceptphase 3

Their studies: Amgen’s studies of Colorectal Neoplasms in search

Coronary Artery Diseaseboth · compare here

Daiichi Sankyo in Coronary Artery Disease: 2 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study

Their studies: Daiichi Sankyo’s studies of Coronary Artery Disease in search

Amgen in Coronary Artery Disease: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Coronary Artery Disease in search

Diabetes Mellitus, Type 2both · compare here

Daiichi Sankyo in Diabetes Mellitus, Type 2: 1 program

  1. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Diabetes Mellitus, Type 2 in search

Amgen in Diabetes Mellitus, Type 2: 2 programs

  1. maridebart cafraglutidephase 3
  2. AMG 127phase 1

Their studies: Amgen’s studies of Diabetes Mellitus, Type 2 in search

Neoplasmsboth · compare here

Daiichi Sankyo in Neoplasms: 1 program

  1. patritumab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Neoplasms in search

Amgen in Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Neoplasms in search

Prostatic Neoplasmsboth · compare here

Daiichi Sankyo in Prostatic Neoplasms: 1 program

  1. valemetostatphase 1

Their studies: Daiichi Sankyo’s studies of Prostatic Neoplasms in search

Amgen in Prostatic Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. xaluritamigphase 3

Their studies: Amgen’s studies of Prostatic Neoplasms in search

Cardiovascular Diseasesboth · compare here

Daiichi Sankyo in Cardiovascular Diseases: 1 program

  1. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Cardiovascular Diseases in search

Amgen in Cardiovascular Diseases: 1 program

  1. olpasiranphase 3

Their studies: Amgen’s studies of Cardiovascular Diseases in search

Show all 13

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetDaiichi SankyoAmgen
KRASolomorasibsotorasibrule, Pan-KRAS Inhibitor AMG 410rule
A target, or a pathogen for a vaccine, known for: Daiichi Sankyo 14 of 20 · Amgen 17 of 24 programs (27 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.